Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Change in Cash (2016 - 2025)

Historic Change in Cash for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$76.8 million.

  • ImmunityBio's Change in Cash fell 32344.8% to -$76.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$51.0 million, marking a year-over-year increase of 2277.98%. This contributed to the annual value of -$121.9 million for FY2024, which is 17578.25% down from last year.
  • According to the latest figures from Q3 2025, ImmunityBio's Change in Cash is -$76.8 million, which was down 32344.8% from $77.0 million recorded in Q2 2025.
  • ImmunityBio's 5-year Change in Cash high stood at $134.5 million for Q3 2023, and its period low was -$144.7 million during Q1 2022.
  • For the 5-year period, ImmunityBio's Change in Cash averaged around $1.4 million, with its median value being $480000.0 (2022).
  • In the last 5 years, ImmunityBio's Change in Cash tumbled by 158213.85% in 2022 and then skyrocketed by 1812708.33% in 2023.
  • Quarter analysis of 5 years shows ImmunityBio's Change in Cash stood at $116.6 million in 2021, then plummeted by 99.59% to $480000.0 in 2022, then surged by 18127.08% to $87.5 million in 2023, then crashed by 63.87% to $31.6 million in 2024, then plummeted by 342.96% to -$76.8 million in 2025.
  • Its Change in Cash stands at -$76.8 million for Q3 2025, versus $77.0 million for Q2 2025 and -$82.8 million for Q1 2025.